UK Markets closed

Targeted Oncology Therapeutics: Success of CAR-T Technology for the Treatment of Haematology Cancers

·2-min read

Dublin, Nov. 03, 2021 (GLOBE NEWSWIRE) -- The "Targeted Oncology Therapeutics: Hematology Cancers" report has been added to's offering.

There is a strong trend in oncology toward therapeutics that focus on specific targeting mechanisms to achieve positive outcomes.

The success of CAR-T technology for the treatment of haematology cancers has been a glowing example of the power of molecular manipulation to treat specific conditions.

More than three dozen targeted treatments, using novel pathways and signalling, have achieved results that represent a new era in oncology and antineoplastic therapeutics. These approaches have attracted a growing number of drug developers anxious to profit from therapies that can ease the physical, psychological, and emotional burden of cancer. Efforts to re-focus and apply this technology to solid tumours is now aggressively being pursued by a growing list of market participants. This report examines leading mAb and kinase inhibitor therapeutic drugs and the biomarkers they utilize.

Target Oncology Haematology Cancers - What You Will Learn

  • What is the market share of approved haematology cancer therapeutics?

  • What is the global supply picture for targeted haematology cancer therapeutics?

  • Who are the market leaders, by Indication? by Product?

  • What is the therapeutic coverage across all oncology indications? What are the product opportunities?

  • What are the established products in this space? by target, indication, API class, revenue?

  • What is the competitive picture for the haematology cancer market segments?

  • Drug treatment resources

  • Competitive therapy map

  • Clinical trial activity

  • Who are the leading competitors in the field of next-generation haematology cancer therapeutics?

Key Topics Covered:

  • Executive Summary

  • Targeted Oncology Therapeutics

  • Hematology Cancers

  • Executive Summary

  • The Recombinant Drug Ecosystem

  • mAbs and Targeted Oncology Therapeutics

  • Leukemias

  • Acute Lymphocytic Leukemia

  • Chronic Lymphocytic Leukemia

  • Childhood Acute Lymphoblastic Leukemia

  • Acute Myeloid Leukemia

  • Chronic Myelogenous Leukemia

  • Lymphomas

  • Hodgkin Lymphoma

  • Non-Hodgkin's Lymphoma

  • Multiple Myeloma

  • Biological Drugs for Hematology Cancers

  • Monoclonal Antibodies (Twelve Therapeutic Products)

  • Tyrosine Kinase Inhibitors

  • ALL with Philadelphia chromosome (Ph+ ALL)

  • FDA Approved TKIs (Six Therapeutic Products)

  • Chimeric Antigen Receptor-T (CAR-T) (Five Products)

  • The Therapeutic Market Landscape

  • Diagnostic Tools

  • Drugs in Development - The Clinical Trial Picture

  • Leukemias

  • Lymphomas

  • Myeloma

  • FDA-Approved Targeted Oncology

  • Therapeutics for Hematology Cancers

Companies Mentioned

  • Amgen

  • Astellas

  • AstraZeneca

  • Bristol-Myers Squibb

  • Celltrion

  • Daiichi Sankyo

  • Eli Lilly

  • Genentech

  • Genzyme

  • GlaxoSmithKline

  • Janssen Biotech

  • Kyowa Kirin

  • Merck Sharp & Dohme

  • Mylan GmbH

  • Pfizer

  • Regeneron Pharmaceuticals

  • Samsung Bioepis

  • Spetrum Pharmaceuticals

  • United Therapeutics

  • Roche

  • EMD Serono

  • Immunex

  • Lonza Biologics

  • Lonza AG

  • Seattle Genetics

  • Biogen

For more information about this report visit

CONTACT: CONTACT: Laura Wood, Senior Press Manager For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting